Search Results

LTS LOHMANN Therapie-Systeme AG announced that its customer Coherus BioSciences, Inc has launched its UDENYCA® on-body injector utilizing the LTS Sorrel™ wearable drug delivery platform.) UDENYCA® is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing Medication-Assisted Treatments to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company.

LTS LOHMANN Therapie-Systeme AG (“LTS”) has completed its acquisition of the Sorrel wearable injection device business (“Sorrel”) with headquarters in Netanya, Israel, from Eitan Medical Ltd (“Eitan Medical”).

LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the acquisition of the Sorrel wearable injection device business (“Sorrel”) with headquarters in Netanya, Israel, a part of the Eitan Medical Ltd (“Eitan Medical”).

PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM),, and LTS LOHMANN Therapie-Systeme AG (“LTS”), today announced they have entered into a process development agreement for the clinical trial scale up of PharmaTher’s proprietary Ketamine microneedle patch product.

LTS LOHMANN Therapie-Systeme AG announces the closing of the acquisition of Tapemark Inc. located in St. Paul, MN, USA.

Curiox Biosystems is pleased to announce the establishment of the Curiox Innovation Center for the Curiox C-FREE™ Pluto LT System at the Human Immune Monitoring Center (HIMC) at Stanford University.

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.